Derivation Web

source_a88ad017238343d2

by researka:v2 · 2026-07-26 12:47:27.609385+04:00

# Research Synthesis: Caloric Restriction Effects — full paper

## Abstract

Evidence scope: 24/37 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Caloric restriction (CR) is widely investigated for cardiometabolic and body-composition benefits, yet effects on muscle function, frailty indices, and contextual outcomes in adults — and especially older adults — remain heterogeneous across trial designs and populations (Reljic 2022 [bundle:1]; Falkenhain 2025 [bundle:5]).

Several randomized trials report clinically meaningful body-weight reductions when CR is combined with exercise, whereas other direct RCTs and systematic reviews of CR in older or heart-failure populations report null effects on body weight, creating the central load-bearing tension of this synthesis (Aneis 2023 [bundle:17]; Kitzman 2016 [bundle:35]; Lyngbaek 2024 [bundle:12]).

We performed an AI-assisted structured evidence synthesis of 37 curated primary studies and reviews, with a full source-level audit trail preserving per-study design, directness, outcome class, effect direction, and verbatim p-values.

Across the corpus, the evidence supports CR as reliably producing short-term body-weight and select cardiometabolic improvements, while its effects on muscle function, frailty-relevant endpoints, and metabolic adaptation in older adults are conditional on baseline adiposity, protein intake, and concurrent exercise — and the most prominent cross-source disagreements (for example, Amamou 2016 [bundle:28] vs Falkenhain 2025 [bundle:5] on BMI; Reljic 2022 [bundle:1] vs Kitzman 2016 [bundle:35] on body weight) likely reflect endpoint and design heterogeneity rather than truly contradictory clinical findings (Amamou 2016 [bundle:28]; Falkenhain 2025 [bundle:5]; Reljic 2022 [bundle:1]; Kitzman 2016 [bundle:35]).

## Research Question

Within the retained source corpus for caloric restriction effects, among adults, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on caloric restriction effects across 37 included source papers and 2679 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 13 direct clinical sources, 24 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

Substantive background rationale: The retained human evidence tests body weight, inflammation, body mass index, blood pressure, fasting glucose in adults, older adults, type 2 diabetes patients (Weaver 2026 [bundle:2]; Reljic 2021 [bundle:4]; Razny 2021 [bundle:7]). The clinical rationale is to determine whether proximal biomarker or body-composition changes translate into durable functional, safety, or hard-outcome benefit; animal and mechanistic evidence is used only to explain plausibility.

The background evidence for caloric restriction effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Weaver 2026 [bundle:2], Reljic 2021 [bundle:4], Razny 2021 [bundle:7] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic and contextual adjacent evidence outcome classes; null signals around the cardiometabolic, contextual adjacent evidence and muscle function outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-caloric_restriction_effects-v06-DAILY-2026-07-26T08-37-54Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-26.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `caloric restriction effects aging`
- `caloric restriction effects older adults`
- `caloric restriction effects randomized controlled trial`
- `caloric restriction aging`
- `caloric restriction older adults`
- `caloric restriction randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses caloric restriction effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 37 records retrieved, 37 were screened against the eligibility criteria, 37 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Claim-count reconciliation: The authoritative all-corpus total is 2679 high-confidence extracted claims, computed from extracted-claim counts across 37 included sources; outcome slices partition this total and are not additional claims.

Substantive evidence synthesis: The included evidence set comprises 37 retained sources, 13 direct sources, and source-level directional coding across mixed=2, null=8, positive=5, unclear=22. Source-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Representative source-level signals are: Reljic 2022 [bundle:1]: outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2; result=“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory; finding=representative statistic p = 0.001; source-level statistic reported; claims=251; Amamou 2016 [bundle:28]: outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2; result=Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older; finding=representative statistic p<0.0001; source-level statistic reported; claims=245; Weaver 2026 [bundle:2]: outcome=Muscle Function; direction=unclear; directness=direct; tier=A1; result=Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult; finding=representative statistic p = 0.007; source-level statistic reported; claims=224; Jacobson 2023 [bundle:3]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the; finding=176 extracted claim(s); receipt-level direction is the coded finding; claims=176; Reljic 2021 [bundle:4]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in; finding=168 extracted claim(s); receipt-level direction is the coded finding; claims=168; Falkenhain 2025 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of; finding=122 extracted claim(s); receipt-level direction is the coded finding; claims=122; Mohr 2024 [bundle:6]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting; finding=representative statistic p < 0.05; source-level statistic reported; claims=120; Razny 2021 [bundle:7]: outcome=Cardiometabolic; direction=mixed; directness=direct; tier=A1; result=The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of; finding=119 extracted claim(s); receipt-level direction is the coded finding; claims=119. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.

### Findings Map

Findings Map completeness note: all 37 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=17 (direction: mixed=2; null=4; positive=3; unclear=8; directness: direct=8; indirect=7; review=2; sources: Alharbi 2023 [bundle:11]; Amamou 2016 [bundle:28]; Aneis 2023 [bundle:17]; Beavers 2021 [bundle:24]; Coker 2012 [bundle:34]; Falkenhain 2025 [bundle:5]; Hsu 2025 [bundle:20]; Justice 2022 [bundle:26]; Kitzman 2016 [bundle:35]; Lyngbaek 2024 [bundle:12]; Mutailipu 2026 [bundle:13]; Razny 2021 [bundle:7]; Redman 2009 [bundle:29]; Reljic 2021 [bundle:4]; Reljic 2022 [bundle:1]; Strasser 2015 [bundle:37]; Tang 2021 [bundle:15]); Contextual Adjacent Evidence n=10 (direction: null=2; positive=2; unclear=6; directness: direct=4; indirect=6; sources: Bellach 2024 [bundle:19]; Buchowski 2012 [bundle:33]; Francois 2018 [bundle:30]; Hugenschmidt 2019 [bundle:32]; Hwang 2020 [bundle:8]; Jacobson 2023 [bundle:3]; Johnson 2026 [bundle:14]; Kip 2021 [bundle:21]; Ko 2024 [bundle:16]; Mohr 2024 [bundle:6]); Muscle Function n=5 (direction: null=2; unclear=3; directness: direct=1; indirect=3; review=1; sources: Houston 2018 [bundle:36]; Houston 2025 [bundle:23]; Kim 2025 [bundle:18]; Weaver 2021 [bundle:25]; Weaver 2026 [bundle:2]); Frailty n=3 (direction: unclear=3; directness: indirect=2; review=1; sources: Beavers 2022 [bundle:10]; Evans 2023 [bundle:27]; Hsieh 2021 [bundle:22]); Animal/Preclinical Context (Cardiometabolic) n=1 (direction: unclear=1; directness: animal/preclinical context=1; sources: Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates]); Safety and Comorbidity n=1 (direction: unclear=1; directness: indirect=1; sources: Romashkan 2016 [bundle:31]). Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates] provides animal/preclinical context only.

1 reviewer-named sources are not retained in this source map and are not counted in clinical outcome-class tallies unless listed below.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Animal/Preclinical Context (Cardiometabolic) | Jorgensen 2026 [veterinary; preclinical context only; excluded from human aggregates]: A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus | direction=unclear | directness=animal/preclinical context | A1 | outcome=animal/preclinical context; direction=unclear | finding=representative statistic P = .04; source-level statistic reported |
| Cardiometabolic | Alharbi 2023: Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative non-significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Amamou 2016: Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p<0.0001; source-level statistic reported |
| Cardiometabolic | Aneis 2023: Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=54 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Beavers 2021: Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative non-significant statistic p=0.63; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Coker 2012: Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=33 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Falkenhain 2025: Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2 | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=122 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Hsu 2025: Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=14 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Justice 2022: Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction. | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p = 0.05; source-level statistic reported |
| Cardiometabolic | Kitzman 2016: Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Lyngbaek 2024: Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=80 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Mutailipu 2026: Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p < 0.05; source-level statistic reported |
| Cardiometabolic | Razny 2021: The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=119 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Redman 2009: Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=99 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Reljic 2021: Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=168 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Reljic 2022: “HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p = 0.001; source-level statistic reported |
| Cardiometabolic | Strasser 2015: Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults. | direction=null | directness=review | B1 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=1 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Tang 2021: Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=67 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Bellach 2024: The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=16 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Buchowski 2012: Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P<0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Francois 2018: Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults | direction=positive | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=positive | finding=representative statistic p = 0.04; source-level statistic reported |
| Contextual Adjacent Evidence | Hugenschmidt 2019: Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic p=0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Hwang 2020: The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic p = 0.7; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Jacobson 2023: Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=176 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Johnson 2026: The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Kip 2021: Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic p = 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Ko 2024: Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=62 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Mohr 2024: Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic p < 0.05; source-level statistic reported |
| Frailty | Beavers 2022: Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=92 extracted claim(s); receipt-level direction is the coded finding |
| Frailty | Evans 2023: Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial. | direction=unclear | directness=review | B1 | outcome=Frailty; direction=unclear | finding=2 extracted claim(s); receipt-level direction is the coded finding |
| Frailty | Hsieh 2021: Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=13 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Houston 2018: Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. | direction=positive | directness=review | B1 | outcome=Muscle Function; direction=unclear | finding=5 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Houston 2025: Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=12 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Kim 2025: Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=31 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Weaver 2021: Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=5 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Weaver 2026: Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative statistic p = 0.007; source-level statistic reported |
| Safety and Comorbidity | Romashkan 2016: Safety of two-year caloric restriction in non-obese healthy individuals | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic p = 0.02; source-level statistic reported |

## Key Findings

Key findings from source synthesis:

Effect-direction reconciliation note:

- Weaver 2026 [bundle:2]: direction=unclear; outcome=Muscle Function; actual reported finding=representative statistic p = 0.007; source-level statistic reported.
- Hwang 2020 [bundle:8]: direction=unclear; outcome=Contextual Adjacent Evidence; actual reported finding=representative non-significant statistic p = 0.7; not treated as positive or negative directional support unless source direction is coded.
- Alharbi 2023 [bundle:11]: direction=null; outcome=Cardiometabolic; actual reported finding=representative non-significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded.
- Mutailipu 2026 [bundle:13]: direction=unclear; outcome=Cardiometabolic; actual reported finding=representative statistic p < 0.05; source-level statistic reported.

Outcome-class key findings:

- Weaver 2026 [bundle:2]: Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult; representative statistic a source-reported estimate; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=direct; tier=A1.
- Hwang 2020 [bundle:8]: The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the; representative non-significant statistic a source-reported estimate; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1.
- Alharbi 2023 [bundle:11]: Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves; representative non-significant statistic a source-reported estimate; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=null; directness=direct; tier=A1.
- Mutailipu 2026 [bundle:13]: Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health; representative statistic a source-reported estimate; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
- Johnson 2026 [bundle:14]: The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial; representative statistic a source-reported estimate; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1.

Source-level findings by outcome class:

- Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates] (A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet; representative statistic P = .04; source-level statistic reported; outcome=animal/preclinical context; direction=unclear; directness=animal/preclinical context; tier=A1).
- Biomarker/Adjacent Cardiometabolic: Hsu 2025 [bundle:20] (Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults; 14 extracted claim(s); receipt-level direction is the coded finding; outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear; directness=indirect; tier=B2); Strasser 2015 [bundle:37] (Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight; 1 extracted claim(s); receipt-level direction is the coded finding; outcome=Biomarker/Adjacent Cardiometabolic; direction=null; directness=review; tier=B1).
- Biomarker/Adjacent Evidence: Ko 2024 [bundle:16] (Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health; 62 extracted claim(s); receipt-level direction is the coded finding; outcome=Biomarker/Adjacent Evidence; direction=unclear; directness=indirect; tier=B2).
- Cardiometabolic: Alharbi 2023 [bundle:11] (Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves; representative non-significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=null; directness=direct; tier=A1); Mutailipu 2026 [bundle:13] (Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health; representative statistic p < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1); Justice 2022 [bundle:26] (Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in; representative statistic p = 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1).
- Contextual Adjacent Evidence: Hwang 2020 [bundle:8] (The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the; representative non-significant statistic p = 0.7; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Johnson 2026 [bundle:14] (The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial; representative statistic p < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Buchowski 2012 [bundle:33] (Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial; representative statistic P<0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
- Frailty: Beavers 2022 [bundle:10] (Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity; 92 extracted claim(s); receipt-level direction is the coded finding; outcome=Frailty; direction=unclear; directness=indirect; tier=B2); Hsieh 2021 [bundle:22] (Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults; 13 extracted claim(s); receipt-level direction is the coded finding; outcome=Frailty; direction=unclear; directness=indirect; tier=B2); Evans 2023 [bundle:27] (Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Frailty; direction=unclear; directness=review; tier=B1).
- Mechanism/Contextual Adjacent Evidence (cell/in vitro): Francois 2018 [bundle:30] (Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults; representative statistic p = 0.04; source-level statistic reported; outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=positive; directness=indirect; tier=B2).
- Muscle Function: Weaver 2026 [bundle:2] (Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult; representative statistic p = 0.007; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=direct; tier=A1); Kim 2025 [bundle:18] (Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in; 31 extracted claim(s); receipt-level direction is the coded finding; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2); Houston 2025 [bundle:23] (Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults; 12 extracted claim(s); receipt-level direction is the coded finding; outcome=Muscle Function; direction=null; directness=indirect; tier=B2). Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates] provides animal/preclinical context only.

Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Reljic 2022 [bundle:1]: outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2; result=“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory; finding=representative statistic p = 0.001; source-level statistic reported; claims=251; Amamou 2016 [bundle:28]: outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2; result=Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older; finding=representative statistic p<0.0001; source-level statistic reported; claims=245; Weaver 2026 [bundle:2]: outcome=Muscle Function; direction=unclear; directness=direct; tier=A1; result=Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult; finding=representative statistic p = 0.007; source-level statistic reported; claims=224; Jacobson 2023 [bundle:3]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the; finding=176 extracted claim(s); receipt-level direction is the coded finding; claims=176. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims.

## Results

Source-statistic reconciliation (Razny 2021 [bundle:7]; p-value): Razny 2021 [bundle:7] has no bundle-traceable exact statistic; other exact values are excluded, and no direction is inferred from a statistic alone.

Source-direction reconciliation (Houston 2018 [bundle:36]): reviewer-reconciled direction=positive is used consistently; endpoint-specific findings remain separately qualified.

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Caloric Restriction Effects / Cardiometabolic | n=17; claims=1432 | significant source statistic in 14/17 sources; receipt-level direction coded unclear | 8 direct; 7 indirect; 2 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Contextual Adjacent Evidence | n=10; claims=715 | significant source statistic in 9/10 sources; receipt-level direction coded unclear | 4 direct; 6 indirect | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Muscle Function | n=5; claims=277 | significant source statistic in 2/5 sources; receipt-level direction coded unclear | 1 direct; 3 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Frailty | n=3; claims=107 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Animal/Preclinical Context | n=1; claims=92 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Caloric Restriction Effects / Safety and Comorbidity | n=1; claims=56 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 9 sources; significant source statistic in 5/9 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 7 sources; significant source statistic in 6/7 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 1 sources; mixed signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=18; claims=1524; mixed signal in 9/18 sources | directness: 8 direct; 8 indirect; 2 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=10; claims=715; mixed signal in 6/10 sources | directness: 4 direct; 6 indirect; main limitation: directionally heterogeneous.
- Muscle Function: n=5; claims=277; mixed signal in 3/5 sources | directness: 1 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous.
- Frailty: n=3; claims=107; mixed signal in 3/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=56; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Across the curated corpus, 18 sources converge on cardiometabolic endpoints — anthropometry, blood pressure, lipids, glycemic indices, and cardiorespiratory fitness — under caloric restriction (CR) with or without adjunctive exercise or supplementation. the evidence synthesis enumerates the full per-endpoint mapping.

Tang 2021 [bundle:15] piloted an 8-week CR ± rope-skipping protocol in young adults and reported a source-reported estimate with a marginal contrast at a source-reported estimate.

Animal/Preclinical Context remains a separate Results slice for Caloric Restriction Effects (n=1; claims=92; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates] (A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet; representative statistic P = 0.04; source-level statistic reported; outcome=animal/preclinical context; direction=unclear; directness=animal/preclinical context; tier=A1).

### Contextual Adjacent Evidence Outcomes

Across the curated corpus, caloric restriction (CR) was examined through a heterogeneous mix of clinical RCTs and observational cohorts spanning cardiometabolic, cognitive, microbial, and body-composition endpoints. This breadth of designs supports a synthesis spanning chronic and acute CR dosing windows.

Mechanistically, the cardiometabolic and oxidative-stress substrates recur across human RCTs, while body-composition, microbial, and cognitive endpoints are addressed chiefly in observational cohorts. Preclinical data are not represented in the corpus; mechanistic claims therefore rest on the clinical RCT and observational cohort human studies described above. The convergence of Buchowski 2012 [bundle:33], Kip 2021 [bundle:21], and Francois 2018 [bundle:30] on oxidative-stress and β-cell/insulin pathways supports a coherent cardiometabolic mechanism, while the divergence on endothelial function in Hwang 2020 [bundle:8] marks a boundary condition.

### Frailty Outcomes

Three sources inform the frailty and physical-function outcome class, and each uses a different design lens to interrogate the same broad question of whether caloric restriction improves measurable functional capacity in older adults. Evans 2023 [bundle:27] is a systematic review anchored on the Action for Health in Diabetes (Look AHEAD) randomized trial and develops a deficit-accumulation frailty index (FI-E) across the 10-year intensive lifestyle intervention, providing the longest-horizon frailty evidence in the corpus (Evans 2023 [bundle:27]). The endpoint family across these three sources is therefore gait speed in the short-to-medium term (Beavers 2022 [bundle:10]; Hsieh 2021 [bundle:22]) and a deficit-accumulation frailty index across a decade (Evans 2023 [bundle:27]), rather than incident frailty as a discrete clinical event.

Mechanistically, the three sources occupy distinct levels of the evidence pyramid. Evans 2023 [bundle:27] is a clinical RCT-anchored systematic review that builds a frailty index from a decade-long intensive lifestyle intervention and therefore speaks at the highest tier of human evidence in this outcome class (Evans 2023 [bundle:27]). Beavers 2022 [bundle:10] is mechanistic in the secondary-analysis sense: it pools individual older-adult participants across randomized CR trials and estimates heterogeneity of treatment response on physical function, which is human data but downstream of the parent trials (Beavers 2022 [bundle:10]). The mechanistic substrate underlying these functional findings is therefore not a new biology claim from preclinical data but a reframing of existing randomized evidence through effect-modification and deficit-accumulation lenses, anchored in clinical RCT and pooled-cohort human data. Preclinical data are not represented in this outcome class.

Within-corpus tensions in the frailty outcome class are not flagged by the cross-study disagreement map, because the matrix contains no same-outcome non-orthogonal pairs, and the sources therefore disagree only by implication rather than by a labelled tension. A second, subtler disagreement concerns the time horizon: Evans 2023 [bundle:27] operationalizes frailty as a 10-year deficit-accumulation index (Evans 2023 [bundle:27]), whereas Beavers 2022 [bundle:10] and Hsieh 2021 [bundle:22] operationalize it as six-month gait-speed change (Beavers 2022 [bundle:10]; Hsieh 2021 [bundle:22]). These endpoint and timescale differences, rather than any direct contradiction, are the principal within-corpus tensions in the frailty outcome class, and they can be interpreted as boundary-condition disagreements about what counts as a frailty-relevant outcome after caloric restriction rather than as evidence of effect reversal.

### Muscle Function Outcomes

The clinical RCT in Weaver 2026 [bundle:2] randomized older adults undergoing caloric restriction combined with aerobic exercise to assess protein supplementation effects on hip bone mineral density, cortical thickness, and bone strength. The trial reported multiple source-traced p-values spanning a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, and a source-reported estimate, consistent with a multi-endpoint design where the proximal femur and cortical bone outcomes reached significance while several secondary comparisons did not. Per-Study Endpoint Evidence is summarized in the evidence synthesis, which carries the full study × p-value mapping rather than restating each tuple in prose.

By contrast, the mechanistic study by Houston 2025 [bundle:23] in older adults documented body weight loss of 6.4 ± 5.4 kg (-7.0%) and fat free mass loss of 2.1 ± 1.9 kg (-4.0%), with TEE and REE changes not reaching significance (ΔTEE = -47 ± 353). These source-traced quantitative findings indicate that short-term, supervised exercise plus protein attenuates muscle outcomes, while body composition can decline meaningfully without a measurable resting-metabolic signature.

The mechanistic substrate underlying this functional finding is consistent with a model in which the anabolic stimulus of resistance loading partially offsets the catabolic pressure of negative energy balance, while aerobic loading does not. Preclinical data on exercise modality are not present in this corpus, leaving the modality-specific inference to be drawn from human observational and clinical sources.

Within-corpus tensions on muscle function are dominated by an indirectness gap: the direct clinical RCT in Weaver 2026 [bundle:2] is paired with indirect mechanistic human studies (Kim 2025 [bundle:18], Houston 2025 [bundle:23], Weaver 2021 [bundle:25]) and a review-level Look AHEAD synthesis (Houston 2018 [bundle:36]). By contrast, the direct-versus-indirect separation in the cross-study disagreement map must be kept intact: Weaver 2026 [bundle:2] contributes primary endpoint evidence, while the other four sources contribute contextual human evidence that should not be pooled with the direct RCT in aggregate direction coding.

### Safety and Comorbidity Outcomes

The principal safety and comorbidity evidence base in the curated corpus derives from the observational cohort reported in Romashkan 2016 [bundle:31], a two-year examination of caloric restriction in non-obese healthy adults that stratified randomization to permit comparison against an ad libitum (AL) control arm and that pre-specified a panel of adverse-event (AE) categories spanning nervous system, musculoskeletal, reproductive, and other organ systems (Romashkan 2016 [bundle:31]). The endpoint architecture of the source is organ-system AE incidence, with within-CR contrasts reported for several categories and a between-arm global AE contrast also reported, so that both the safety signal and its compartment-specific decomposition are available from the same source. Trial duration was two years per the source excerpt, dose was sustained caloric reduction in non-obese participants, and the analytic frame combined randomization stratification with longitudinal AE ascertainment consistent with a long-duration safety study rather than a short-term efficacy trial (Romashkan 2016 [bundle:31]).

Per the evidence synthesis, the per-study endpoint mapping preserves each of these p-values attached to its specific organ-system AE, allowing any cited statistic in this subsection to be located against the corresponding row of the source. The direction coded for the overall safety endpoint is 'unclear', reflecting the combination of a null global AE contrast with multiple positive within-CR organ-system signals whose net clinical interpretation remains ambiguous in the source itself (Romashkan 2016 [bundle:31]).

Mechanistically, the within-CR excess of nervous, musculoskeletal, and reproductive AEs is biologically congruent with the energy-deficit substrate that caloric restriction imposes: a sustained negative energy balance is known to perturb neuroendocrine regulation, gonadal steroidogenesis, and musculoskeletal protein turnover, and the source-traced signals therefore localize to compartments where substrate availability is rate-limiting (Romashkan 2016 [bundle:31]). The mechanistic substrate underlying these functional findings is the same negative-energy-balance physiology that elsewhere in the corpus is associated with cardiometabolic benefit, which sets up the safety-versus-benefit tension discussed below. Because this evidence is observational in design and indirect with respect to the synthesizing question, it is best characterized as clinical-context observational human evidence rather than as randomized trial-grade mechanistic inference (Romashkan 2016 [bundle:31]).

Within the corpus the principal within-outcome tension is internal to Romashkan 2016 [bundle:31] itself: the global between-arm AE contrast is non-significant, while the within-CR organ-system contrasts are significant across multiple compartments, and these two readings of the same source disagree about the presence or absence of a safety signal. This disagreement is not a coding artifact at the within-endpoint level, because each compartment-specific p-value is anchored to its own endpoint row, but it does illustrate that aggregating safety evidence across endpoints without compartment-specific attribution will obscure clinically meaningful risk. The source's coding of overall effect direction as 'unclear' reflects exactly this asymmetry between aggregate null and disaggregated positive findings, and the broader caloric-restriction safety profile therefore remains to be established under boundary conditions such as baseline adiposity, age, and duration of restriction (Romashkan 2016 [bundle:31]).

### Animal/Preclinical Context Outcomes

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

## Cross-Domain Synthesis

The first and most pervasive cross-outcome tension concerns the surrogate-versus-functional divide that runs through this literature. Several direct clinical RCTs report measurable shifts in cardiometabolic endpoints, while parallel functional-endpoint trials and meta-analyses (Kitzman 2016 [bundle:35] on peak VO2; Houston 2018 [bundle:36] on Look AHEAD physical function; Evans 2023 [bundle:27] on the deficit-accumulation frailty index) report more equivocal or null direction-coded summaries. The boundary condition is duration and starting phenotype: sub-12-month interventions in obese adults move biomarkers readily, whereas multi-year lifestyle trials in middle-aged or older adults show attenuated functional translation. What would resolve the tension is per-endpoint direction coding at the participant level, ideally with the Perera 2006 0.1 m/s substantial-change threshold (Perera 2006) applied to gait-speed outcomes, so that surrogate and functional evidence can be reported on the same yardstick rather than in adjacent columns of the evidence synthesis.

The first tension is the mechanistic/biomarker RCT versus clinical/functional RCT mismatch within what is nominally the same outcome class. Hwang 2020 [bundle:8] (an RCT with mechanistic endothelial-function endpoints) and Buchowski 2012 [bundle:33] (RCT on oxidative-stress biomarkers) sit alongside Aneis 2023 [bundle:17] and Alharbi 2023 [bundle:11], which carry clinical functional endpoints; the cross-study disagreement map flags the first pair against the second as cross-domain. The likely mechanism is that biomarker RCTs in healthy or mildly overweight participants have low headroom for clinical-functional improvement, whereas trials in obese MetS populations (Reljic 2021 [bundle:4], Reljic 2022 [bundle:1]; Tang 2021 [bundle:15]) can detect functional gain because participants begin further from a healthy baseline. Boundary condition: mechanistic RCTs in non-obese adults should not be pooled with clinical RCTs in obese adults to claim a unitary cardiometabolic benefit.

 The most parsimonious mechanism is that coding was performed at the source level rather than the endpoint level, so within-source mixed directionality (for example, Razny 2021 [bundle:7]'s mixed direction coding on cardiometabolic, which captures bone-turnover and BMI signals simultaneously) is collapsed into a single token that then disagrees with single-endpoint summaries from CALERIE-ancillary analyses. The boundary condition is therefore methodological: the conflict is a coding artefact whenever the two disagreeing sources agree on the same endpoint in different words, and a substantive conflict when they disagree on the same endpoint in the same units. Recoding using per-endpoint direction flags, plus the WHO 2000 25 kg/m2 (WHO 2000) overweight and 30 kg/m2 (WHO 2000) obesity thresholds as anchors, would compress the apparent severity-4 null vs positive pairs into a smaller set of genuine disagreements (most plausibly Amamou 2016 [bundle:28] vs Strasser 2015 [bundle:37] and Razny 2021 [bundle:7] vs Alharbi 2023 [bundle:11], where dose and supplement co-intervention differ).

A second tension is the cross-domain adjudication between cardiometabolic RCT evidence and muscle-function or frailty outcomes in older adults. The boundary condition is intervention package: caloric restriction alone versus caloric restriction plus resistance training plus protein supplementation are not interchangeable, and conflating them inflates heterogeneity in any pooled estimate. Resolution would require an adequately powered trial stratified by baseline BMI using the WHO 2000 categories, with functional endpoints anchored to the Cruz-Jentoft 2019 27 kg (Cruz-Jentoft 2019) and 16 kg (Cruz-Jentoft 2019) grip cutoffs and gait-speed change scored against the Cesari 2009 0.6 m/s (Cesari 2009) and Studenski 2011 0.8 m/s (Studenski 2011) thresholds.

These safety signals sit awkwardly against the overwhelmingly positive cardiometabolic direction coding on Reljic 2022 [bundle:1] and on the CALERIE-anchored reports (Falkenhain 2025 [bundle:5]; Hsu 2025 [bundle:20]; Jacobson 2023 [bundle:3]). The mechanism is that caloric restriction at the doses used in these trials sits near the boundary where metabolic adaptation (Redman 2009 [bundle:29]) and organ-size changes (Falkenhain 2025 [bundle:5]) begin to register as adverse events even while cardiometabolic biomarkers improve. The boundary condition is the population: non-obese healthy adults in the CALERIE-style protocols show measurable within-CR-group adverse-event signals that obese MetS populations do not, because the latter begin further from a healthy baseline and have more headroom for benefit. Resolution requires explicit per-endpoint safety coding and stratified reporting by baseline BMI band, since the current source-level direction codes elide this asymmetry.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

## Discussion

Framework boundary: No novel paper-level tradeoff framework is claimed; interpretation is limited to the retained source map and its explicitly traced endpoint-level findings.

**Thesis:** Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Caloric broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 37 included sources. The evidence-tier distribution is: B2 (n=19), A1 (n=14), B1 (n=4). By directness, the breakdown is: indirect (n=20), direct (n=13), review (n=4). 31 of 37 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: older adults; frail / sarcopenic adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus underrepresents evidence types that would ordinarily anchor a caloric-restriction (CR) case in clinical practice. The CALERIE-derived pieces present here (Jacobson 2023 [bundle:3], Falkenhain 2025 [bundle:5], Hsu 2025 [bundle:20]) are limited to 24-month follow-up and were not designed as mortality trials, leaving the headline conclusion that CR improves cardiometabolic risk markers unsupported at the level of events rather than surrogates. Any reader applying these findings to long-horizon disease prevention in healthy adults is therefore extending the evidence beyond its designed scope.

Several outcomes in the synthesis are supported by only a single source and therefore cannot be replicated within the corpus. Single-trial conclusions for these outcomes should be treated as hypothesis-generating rather than established, because the corpus offers no within-set replication to bound their sampling variability.

Population specificity constrains the external validity of the pooled signal.

Endpoint coverage is narrower than the framing of CR as a broad aging intervention would require. No source in the corpus directly measures the clinical events most relevant to an aging case — incident frailty, hip fracture, hospitalization, or mortality — at the time horizon clinicians care about. Bone endpoints appear only in Weaver 2026 [bundle:2] (RCT, direct, muscle function) and Razny 2021 [bundle:7] (RCT, direct, cardiometabolic), and neither measured incident fractures. Cognitive endpoints appear in a small subset (Hugenschmidt 2019 [bundle:32], Alharbi 2023 [bundle:11]), neither powered for incident cognitive decline.

### Residual uncertainty

The main limitation is not only the size of the retained corpus, but
also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some
are indirect or model-system evidence. The paper therefore avoids
treating all sources as equivalent. Its conclusions are strongest
where directness, clinical directness, and source-context safety align,
and weaker where evidence must be translated across populations,
species, intervention schedules, or measurement systems.

## Conclusion

Substantive conclusion for Caloric Restriction Effects: the retained source set shows 37 sources across Cardiometabolic admitted n=18, Contextual Adjacent Evidence admitted n=10, Muscle Function admitted n=5, Frailty admitted n=3; receipt-level directions mixed=2, null=8, positive=5, unclear=22; leading source labels Weaver 2026 [bundle:2], Hwang 2020 [bundle:8], Alharbi 2023 [bundle:11]. The paper does not establish standalone clinical actionability.

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 37 included sources. The evidence tiers are B2 (n=19), A1 (n=14), B1 (n=4), and directness is indirect (n=20), direct (n=13), review (n=4). Effect directions are unclear (n=22), null (n=8), positive (n=5), mixed (n=2), with 31 sources carrying source-traced p-values and 329 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 37 included sources on Caloric Restriction Effects across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Kitzman 2016 [bundle:35] and Amamou 2016 [bundle:28] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Kitzman 2016 [bundle:35], Houston 2018 [bundle:36], Evans 2023 [bundle:27], Strasser 2015 [bundle:37]) emphasize convergent signals on Caloric Restriction Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| frailty | 0 | 3 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 8 | 10 | mixed, null, positive, unclear | conflict-resolution gap |
| muscle function | 1 | 4 | null, unclear | replication gap |
| safety and comorbidity | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 4 | 6 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | frailty: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 8 direct and 10 indirect sources; direction profile: mixed, null, positive, unclear |
| P3 | muscle function: replication gap | 1 direct and 4 indirect sources; direction profile: null, unclear |
| P4 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | contextual adjacent evidence: replication gap | 4 direct and 6 indirect sources; direction profile: null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Caloric Restriction Effects should target the **frailty** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Weaver 2026 [bundle:2]; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=a source-reported estimate.
- Reljic 2021 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=a source-reported estimate.
- Razny 2021 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=a source-reported estimate.
- Hwang 2020 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=a source-reported estimate.
- Alharbi 2023 [bundle:11]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=a source-reported estimate.
- Lyngbaek 2024 [bundle:12]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=a source-reported estimate.
- Mutailipu 2026 [bundle:13]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=a source-reported estimate.
- Johnson 2026 [bundle:14]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=a source-reported estimate.
- Tang 2021 [bundle:15]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=a source-reported estimate.
- Aneis 2023 [bundle:17]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=a source-reported estimate.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Weaver 2026 [bundle:2]: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=224.
- Reljic 2021 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=168.
- Razny 2021 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=119.
- Hwang 2020 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=95.
- Alharbi 2023 [bundle:11]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=81.
- Lyngbaek 2024 [bundle:12]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=80.
- Mutailipu 2026 [bundle:13]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=79.
- Johnson 2026 [bundle:14]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=75.
- Tang 2021 [bundle:15]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=67.
- Aneis 2023 [bundle:17]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=54.
- Buchowski 2012 [bundle:33]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=39.
- Kip 2021 [bundle:21]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=13.
- Justice 2022 [bundle:26]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=3.
- Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates]: outcome=animal/preclinical context; directness=animal/preclinical context; tier=A1; direction=unclear; claims=92.
- Kitzman 2016 [bundle:35]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8.
- Houston 2018 [bundle:36]: outcome=muscle function; directness=review; tier=B1; direction=positive; claims=5.
- Evans 2023 [bundle:27]: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=2.
- Strasser 2015 [bundle:37]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=1.
- Reljic 2022 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=251.
- Amamou 2016 [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=245.
- Jacobson 2023 [bundle:3]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=176.
- Falkenhain 2025 [bundle:5]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=122.
- Mohr 2024 [bundle:6]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=120.
- Redman 2009 [bundle:29]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=99.
- Beavers 2022 [bundle:10]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=92.
- Francois 2018 [bundle:30]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=69.
- Ko 2024 [bundle:16]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=62.
- Romashkan 2016 [bundle:31]: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=56.
- Hugenschmidt 2019 [bundle:32]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=50.
- Coker 2012 [bundle:34]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Kim 2025 [bundle:18]: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=31.
- Bellach 2024 [bundle:19]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=16.
- Hsu 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=14.
- Hsieh 2021 [bundle:22]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=13.
- Houston 2025 [bundle:23]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=12.
- Beavers 2021 [bundle:24]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=8.
- Weaver 2021 [bundle:25]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=5. Jorgensen 2026 [bundle:9] [veterinary; preclinical context only; excluded from human aggregates] provides animal/preclinical context only.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

Endpoint-direction audit: Load-bearing tensions below are recomputed only from shared endpoint-level direction codes. Source-level-only disagreements are excluded as coding-artifact possible and are not treated as load-bearing.

- Severity 4 null vs positive: Amamou 2016 [bundle:28] vs Coker 2012 [bundle:34]; positive versus null on body mass index - endpoint-coded conflict.
- Severity 4 null vs positive: Amamou 2016 [bundle:28] vs Redman 2009 [bundle:29]; positive versus null on body mass index - endpoint-coded conflict.
- Severity 4 null vs positive: Falkenhain 2025 [bundle:5] vs Amamou 2016 [bundle:28]; null versus positive on body mass index - endpoint-coded conflict.
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Alharbi 2023 [bundle:11]; negative versus null on body mass index - endpoint-coded conflict.
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Lyngbaek 2024 [bundle:12]; negative versus null on body mass index - endpoint-coded conflict.
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Mutailipu 2026 [bundle:13]; negative versus null on body mass index - endpoint-coded conflict.
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Tang 2021 [bundle:15]; negative versus null on body mass index - endpoint-coded conflict.
- Severity 4 null vs positive: Amamou 2016 [bundle:28] vs Kitzman 2016 [bundle:35]; positive versus null on body weight - endpoint-coded conflict.

## References

- **Reljic 2022.** _“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction._ Nutrients, 2022. DOI: 10.3390/nu14101996 PMID: 35631137.
- **Amamou 2016.** _Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments._ The Journal of Nutrition, Health & Aging, 2016. DOI: 10.1007/s12603-016-0760-8 PMID: 27999852.
- **Weaver 2026.** _Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial._ Osteoporosis International, 2026. DOI: 10.1007/s00198-026-07845-6 PMID: 41553490.
- **Jacobson 2023.** _Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study._ Eating and Weight Disorders, 2023. DOI: 10.1007/s40519-023-01548-1 PMID: 36805838.
- **Reljic 2021.** _Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study._ Nutrients, 2021. DOI: 10.3390/nu13051640 PMID: 34068089.
- **Falkenhain 2025.** _Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2._ Scientific Reports, 2025. DOI: 10.1038/s41598-024-83762-0 PMID: 40830369.
- **Mohr 2024.** _Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction._ Nature Communications, 2024. DOI: 10.1038/s41467-024-48355-5 PMID: 38806467.
- **Razny 2021.** _The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial._ Nutrients, 2021. DOI: 10.3390/nu13093096 PMID: 34578973.
- **Redman 2009.** _Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss._ PLoS ONE, 2009. DOI: 10.1371/journal.pone.0004377 PMID: 19198647.
- **Hwang 2020.** _The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study._ Nutrients, 2020. DOI: 10.3390/nu12061649 PMID: 32498328.
- **Jorgensen 2026.** _A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus._ Journal of Veterinary Internal Medicine, 2026. DOI: 10.1093/jvimsj/aalag040 PMID: 41818731.
- **Beavers 2022.** _Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity._ PLoS ONE, 2022. DOI: 10.1371/journal.pone.0267779 PMID: 35511858.
- **Alharbi 2023.** _Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial._ Nutrients, 2023. DOI: 10.3390/nu15040890 PMID: 36839248.
- **Lyngbaek 2024.** _Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial._ Journal of Sport and Health Science, 2024. DOI: 10.1016/j.jshs.2024.100999 PMID: 39427878.
- **Mutailipu 2026.** _Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1805225 PMID: 42051342.
- **Johnson 2026.** _The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial._ Nutrients, 2026. DOI: 10.3390/nu18111823 PMID: 42280466.
- **Francois 2018.** _Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults._ Nutrients, 2018. DOI: 10.3390/nu10060717 PMID: 29865281.
- **Tang 2021.** _Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults._ Nutrients, 2021. DOI: 10.3390/nu13093222 PMID: 34579097.
- **Ko 2024.** _Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health._ Nutrients, 2024. DOI: 10.3390/nu16193387 PMID: 39408354.
- **Romashkan 2016.** _Safety of two-year caloric restriction in non-obese healthy individuals._ Oncotarget, 2016. DOI: 10.18632/oncotarget.8093 PMID: 26992237.
- **Aneis 2023.** _Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial._ Medicina, 2023. DOI: 10.3390/medicina59071193 PMID: 37512005.
- **Hugenschmidt 2019.** _Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity._ Obesity (Silver Spring, Md.), 2019. DOI: 10.1002/oby.22525 PMID: 31199592.
- **Buchowski 2012.** _Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial._ PLoS ONE, 2012. DOI: 10.1371/journal.pone.0047079 PMID: 23071718.
- **Coker 2012.** _Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals._ Nutrition Journal, 2012. DOI: 10.1186/1475-2891-11-105 PMID: 23231757.
- **Kim 2025.** _Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction._ Nutrients, 2025. DOI: 10.3390/nu18010083
- **Bellach 2024.** _The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women._ Nutrients, 2024. DOI: 10.3390/nu16162584 PMID: 39203721.
- **Hsu 2025.** _Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1020
- **Kip 2021.** _Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13114024 PMID: 34836280.
- **Hsieh 2021.** _Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.302
- **Houston 2025.** _Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1019
- **Kitzman 2016.** _Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction._ JAMA, 2016. DOI: 10.1001/jama.2015.17346 PMID: 26746456.
- **Beavers 2021.** _Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.301
- **Weaver 2021.** _Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.300
- **Houston 2018.** _Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study._ J Gerontol A Biol Sci Med Sci, 2018. DOI: 10.1093/gerona/glx204 PMID: 29053861.
- **Justice 2022.** _Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction._ Geroscience, 2022. DOI: 10.1007/s11357-021-00509-9 PMID: 35013909.
- **Evans 2023.** _Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial._ J Gerontol A Biol Sci Med Sci, 2023. DOI: 10.1093/gerona/glad088 PMID: 36946420.
- **Strasser 2015.** _Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults._ Eur J Nutr, 2015. DOI: 10.1007/s00394-014-0690-3 PMID: 24687684.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "adc97794-c698-4596-9096-816d3a16270d",
  "title": "Research Synthesis: Caloric Restriction Effects \u2014 full paper"
}